Drug intelligence / Profile preview

XYL-3001

Development stage: Preclinical
Lead developer: Xylo Bio
Modality: Small Molecules

Overview

XYL-3001 (formerly PSYLO-3001) is a non-hallucinogenic small molecule serotonin 5-HT2A receptor agonist being developed by Xylo Bio (formerly Psylo). Classified as a psychoplastogen, the drug is designed to enhance neuroplasticity by stimulating the growth and remodeling of neural circuits without inducing the hallucinogenic effects typically associated with psychedelic compounds. XYL-3001 is currently in preclinical development for the treatment of psychiatric conditions, including depressive disorders, generalized anxiety disorder, and social phobia.

Targets

HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on XYL-3001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XYL-3001.